Profile data is unavailable for this security.
About the company
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
- Revenue in HKD (TTM)282.19m
- Net income in HKD-237.81m
- Incorporated2018
- Employees429.00
- LocationAlphamab OncologyNo. 175Fangzhou Road, Suzhou Industrial ParkSuzhou 215125ChinaCHN
- Phone+86 51 262850800
- Websitehttps://www.alphamabonc.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jacobio Pharmaceuticals Group Co Ltd | 25.57m | -399.12m | 1.33bn | 298.00 | -- | 1.34 | -- | 52.17 | -0.5142 | -0.5142 | 0.0329 | 1.26 | 0.016 | -- | 2.41 | 84,951.02 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
Immunotech Biopharm Ltd | 0.00 | -341.03m | 1.46bn | 211.00 | -- | 16.34 | -- | -- | -0.6627 | -0.6627 | 0.00 | 0.1738 | 0.00 | -- | -- | 0.00 | -35.21 | -37.42 | -55.75 | -45.48 | -- | -- | -- | -- | 0.3638 | -2.44 | 0.6119 | -- | -- | -- | -5.25 | -- | -8.46 | -- |
TOT Biopharm International Co Ltd | 1.07bn | 9.89m | 1.55bn | 551.00 | 146.72 | 1.94 | 22.07 | 1.44 | 0.0136 | 0.0136 | 1.48 | 1.03 | 0.6899 | 2.44 | 6.35 | 1,947,891.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
CARsgen Therapeutics Holdings Ltd | 6.99m | -766.37m | 1.75bn | 477.00 | -- | 1.07 | -- | 250.12 | -1.38 | -1.38 | 0.0126 | 2.87 | 0.0027 | -- | 0.302 | 13,550.88 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
Laekna Inc | 0.00 | -325.94m | 1.83bn | 92.00 | -- | 2.45 | -- | -- | -0.9147 | -0.9147 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
ImmuneOnco Biopharmaceuticls Shanghi Inc | -100.00bn | -100.00bn | 1.87bn | 145.00 | -- | 2.83 | -- | -- | -- | -- | -- | 1.77 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
CStone Pharmaceuticals | 503.50m | -156.95m | 1.89bn | 164.00 | -- | 3.66 | -- | 3.75 | -0.1232 | -0.1232 | 0.3949 | 0.4016 | 0.2861 | 1.33 | 2.50 | 2,189,134.00 | -8.92 | -54.76 | -16.99 | -81.68 | 70.73 | -- | -31.17 | -301.62 | 1.45 | -- | 0.4171 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
Abbisko Cayman Ltd | 548.43m | -17.87m | 2.14bn | 275.00 | -- | 0.9283 | 587.33 | 3.90 | -0.0303 | -0.0303 | 0.8444 | 3.36 | 0.2159 | -- | -- | 2,125,706.00 | -0.7034 | -- | -0.733 | -- | 100.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
Biocytogen Pharmaceuticals Beijng Co Ltd | 882.94m | -268.90m | 2.52bn | 1.04k | -- | 3.08 | -- | 2.85 | -0.6752 | -0.6752 | 2.22 | 2.04 | 0.3109 | 23.64 | 5.35 | 828,271.80 | -9.47 | -- | -12.44 | -- | 71.97 | -- | -30.46 | -- | 1.33 | -3.22 | 0.436 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
Alphamab Oncology | 282.19m | -237.81m | 2.56bn | 429.00 | -- | 1.43 | -- | 9.09 | -0.247 | -0.247 | 0.2931 | 1.86 | 0.1145 | 0.8256 | 13.94 | 648,721.30 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
Data as of Sep 23 2024. Currency figures normalised to Alphamab Oncology's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 04 Sep 2024 | 23.84m | 2.47% |
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 16.02m | 1.66% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 12.24m | 1.27% |
First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 8.52m | 0.88% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 7.75m | 0.80% |
China Asset Management Co., Ltd.as of 31 Dec 2023 | 2.19m | 0.23% |
E Fund Asset Management Co. Ltd.as of 30 Jun 2024 | 1.34m | 0.14% |
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 1.18m | 0.12% |
SSgA Funds Management, Inc.as of 05 Sep 2024 | 737.00k | 0.08% |
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 636.00k | 0.07% |
More ▼
Data from 31 Dec 2023 - 19 Sep 2024Source: FactSet Research Systems Inc.